Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marina Biotech has received patent rights from the State Intellectual Property Office of the People's Republic of China (PRC) for its intranasal delivery of insulin.
Subscribe to our email newsletter
The formulation is used to treat diseases associated with inappropriate insulin levels.
Preclinical studies including Phase 1 and multicenter Phase 2 clinical trials have proven the efficacy of the formulation.
Insulin is delivered to the nasal mucosa and does not enter the lungs.
The move is believed to strengthen the insulin patent portfolio in China.